Clinical Roundtable Monograph
نویسنده
چکیده
Proton pump inhibitors (PPIs) are commonly prescribed for the management of upper gastrointestinal tract disorders, and over 2 decades of use have demonstrated that these drugs provide significant clinical benefits with very few serious acute adverse events. However, several recent reports have suggested that short-term and long-term PPI treatment may be associated with certain risks. Specifically, studies have demonstrated a modest magnitude of association (odds ratio <2) between PPI therapy and osteoporotic fractures, micronutrient deficiencies, inhibition of antiplatelet therapy, enteric infections, and pneumonia. In response to some of these studies, the US Food and Drug Administration recently required labeling changes that reflect several of these potential risks. While available studies suggest a possible association between various risks and PPI use, demonstrating a causal link is difficult due to the absence of randomized controlled studies, heterogeneity among available studies, inconsistency of findings, and presence of confounding factors. As with all drug therapies, therefore, clinicians need to weigh the benefit of the therapy against any potential risks. Overall, the absolute risk for the majority of patients is small, and the benefits of these drugs often outweigh their potential risks. A CME Activity Approved for 1.0 AMA PRA Category 1 CreditTM
منابع مشابه
Clinical roundtable monograph. Early death in patients with acute promyelocytic leukemia.
With the introduction of all-trans retinoic acid (ATRA) and arsenic trioxide, acute promyelocytic leukemia (APL) has become a highly curable malignancy. Approximately 90% of patients achieve complete remission with induction, which generally includes ATRA and an anthracycline-based chemotherapy. Early death, either before treatment is initiated or during induction, has emerged as one of the mos...
متن کاملClinical roundtable monograph. New alternatives in CLL therapy: managing adverse events.
Chronic lymphocytic leukemia (CLL) is a B-cell leukemia mainly affecting older adults. Historically, CLL has been regarded as an incurable disease, and treatment has been confined to cytotoxic chemotherapy regimens. However, prognosis for patients treated with these agents remained poor, prompting the development of new, targeted agents. The introduction of rituximab, a CD20-targeted monoclonal...
متن کاملClinical Roundtable Monograph Discussants
Antibody-drug conjugates (ADCs) combine cytotoxic chemotherapy and antibody specificity. There are 4 components of ADC technology: the cancer, or target, antigen; the antibody to that target; the linker that connects the drug to the antibody; and the drug itself. The antibody directs the cytotoxic agent to the tumor cell, thereby diminishing the side effect profile of the cytotoxic agent and en...
متن کاملClinical Roundtable Monograph
Ovarian cancer is a relatively infrequent malignancy, but it is the fifth leading cause of cancer-related mortality in American women. The initial diagnosis of ovarian cancer is usually made when the disease is at an advanced stage. Although advanced ovarian cancer is characteristically sensitive to initial surgical debulking followed by platinum-based combination chemotherapy, it is rarely cur...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره شماره
صفحات -
تاریخ انتشار 2013